What is the Chiome Bioscience Inc. stock price forecast?

Chiome Bioscience Inc. is currently trading at ¥71. View real-time AI analysis on Alpha Lenz.

What is Chiome Bioscience Inc. insider trading activity?

View the latest insider trading data for Chiome Bioscience Inc. on Alpha Lenz.

What is Chiome Bioscience Inc.'s P/E ratio?

Chiome Bioscience Inc.'s P/E ratio is -4.0.

Chiome Bioscience Inc.

JPX · 4583

¥71+3(+4.41%)Market closed

Ask about Chiome Bioscience Inc.'s future dividend policy...

Alpha Chat Insight

“Chiome Bioscience Inc. trades at a P/E of -4.0 (undervalued) with modest ROE of -64.6%.”

Ask for details →

Company Overview

Chiome Bioscience Inc. is a biotechnology company that engages in the research, development, and commercialization of innovative therapeutic solutions, focusing on the development of antibody-based drugs. Established in Japan, the company operates within the highly specialized bio-pharmaceutical sector. Chiome Bioscience is renowned for its proprietary ADLib® system, an antibody generation platform that facilitates the discovery and development of novel monoclonal antibodies, particularly those targeting cancer and autoimmune diseases. By leveraging state-of-the-art biotechnology techniques, the company aims to address unmet medical needs and improve disease management worldwide. Chiome Bioscience's work is crucial in the advancement of next-generation antibody therapies, making it a significant player in the global biopharmaceutical market. Through collaborative partnerships and its cutting-edge research, the company continues to make impactful contributions to scientific innovation and healthcare solutions.

CEODr. Masamichi Koike Ph.D.

Websitehttps://www.chiome.co.jp

SectorHealthcare

IndustryBiotechnology

Company Statistics

FY 2025

Profile

¥3,978,181,830Market Cap

¥593,290,000Revenue

0.00Shares Out

0Employees

Margins

59.93%Gross

-165.56%EBITDA

-165.14%Operating

-165.10%Pre-Tax

-165.65%Net

Valuation

-4.05P/E

3.55P/B

6.71EV/Sales

-3.09EV/EBITDA

-4.08P/FCF

Growth (CAGR)

-2.02%Rev 3Yr

4.29%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-46.84%ROA

-64.61%ROE

-46.53%ROIC

Financial Health

¥1,205,026,000Cash & Cash Equivalents

¥-599,586,000Net Debt

53.96%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Chiome Bioscience Inc. trades at a P/E of -4.0 (undervalued) with modest ROE of -64.6%.”

Ask for details →

Frequently Asked Questions

Chiome Bioscience Inc. (ticker: 4583) is a company listed on JPX in the Healthcare sector (Biotechnology). Market cap is $4.0B.

The current price is 71 with a P/E ratio of -4.05x and P/B of 3.55x.

ROE is -64.61% and operating margin is -165.14%. Annual revenue is $593M.